Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX – Research Report), Tenet Healthcare (THC – Research Report) and Nautilus Biotechnolgy (NAUT – Research Report).
Argenx Se (ARGX)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Argenx Se, with a price target of $533.00. The company’s shares closed last Thursday at $380.01.
According to TipRanks.com, Ahmad is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $479.00 average price target, a 24.2% upside from current levels. In a report issued on February 20, Wells Fargo also maintained a Buy rating on the stock with a $478.00 price target.
See today’s best-performing stocks on TipRanks >>
Tenet Healthcare (THC)
Bank of America Securities analyst Kevin Fischbeck reiterated a Buy rating on Tenet Healthcare yesterday and set a price target of $110.00. The company’s shares closed last Thursday at $93.00, close to its 52-week high of $94.16.
According to TipRanks.com, Fischbeck is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenet Healthcare with a $106.62 average price target, which is a 18.0% upside from current levels. In a report issued on February 15, Wells Fargo also maintained a Buy rating on the stock with a $105.00 price target.
Nautilus Biotechnolgy (NAUT)
Goldman Sachs analyst Matthew Sykes maintained a Hold rating on Nautilus Biotechnolgy on February 28 and set a price target of $2.75. The company’s shares closed last Thursday at $2.69.
According to TipRanks.com, Sykes is a 1-star analyst with an average return of
Currently, the analyst consensus on Nautilus Biotechnolgy is a Moderate Buy with an average price target of $3.88, which is a 33.8% upside from current levels. In a report released yesterday, Morgan Stanley also initiated coverage with a Hold rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARGX:
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- ARGX Upcoming Earnings Report: What to Expect?
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
- Argenx announces FDA acceptance of Vyvgart Hytrulo sBLA for priority review
